## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gene Bright et al.,

APPLICATION NO.: 10/800328 : Examiner: Zachary C. Tucker

FILING DATE: 03/12/2004 : Group Art Unit: 1624

TITLE: PYRIDYLOXYMETHYL AND:

BENZISOXAZOLE AZABICYCLIC
DERIVATIVES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTC/SB/08A which lists the reference cited by the applicant(s).

1. US 5,157,034 10/20/1992

This reference is being provided because it was cited by a foreign patent office in a counterpart application and provided in a communication to our foreign agent. Said agent received said communication on 12 February 2007 and flowarded to Applicants in a letter dated 15 February 2007. Therefore, the reference contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and it is believed that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the fifting of the information disclosure statement.

The Examiner is requested to consider carefully the complete text of these reference in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the reference on the PTO/SB/08A form is not intended to represent or imply that this reference is prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior to

It is requested that the reference listed on the attached form PTO/SB/08A be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 8 March 2007

/Mary J. Hosley/

Mary J. Hosley, Reg. No. 48,324 Attorney for Applicant(s)

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street

New York, NY 10017-5755 (212) 733-0634 unless it displays a valid OMB control number

	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/800328	
STATEMENT BY APPLICANT	Filing Date	03/12/2004	
(use es many sheets as necessery)	First Named Inventor	Gene Bright et al.,	
Supplemental IDS	Art Unit	1624	
	Examiner Name	Zachary C. Tucker	
Sheet 1 of 1	Attorney Docket Number	PC25322A	

U.S. PATENT DOCUMENTS				
Peges, C		Document Number		EXAMINER CRE
blication Date Name of Patentee or Move.	Publication Date MM-DD-YYYY	Number Kind Code <sup>2</sup> (if known)	Cite No. <sup>1</sup>	
10/20/1992	10/20/1992	US 5,157,034		
J0/20/1992	10/20/1992	US 5,157,034		

FOREIGN PATENT DOCUMENTS						
EXAMINER Cite INITIAL No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Oted Document	Pages, Columns, Lines, Where Relevant	Τ.	
		Country Code <sup>®</sup> Number <sup>®</sup> Kind Code <sup>®</sup> (if Innown)	MM-DD-YYYY		Passages or Relevent Figures Appear	г

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1		T <sup>2</sup>

EXAMINER	DATE CONSIDERED	

n is in conformance with MPEP 608. Draw line through citation if not in conformance and not EXAMINER Initial if reference considered, whether or not cita

Author: first interest administration and professions in assessment with the Year. Due to the recognition for in continued and the Application and the state of the Profession and the Profession and the Profession and the Application and the Appli